Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Amylyx Pharmaceuticals Inc (AMLX – Research Report).
Vertex Pharmaceuticals (VRTX)
William Blair analyst Myles Minter initiated coverage with a Buy rating on Vertex Pharmaceuticals today. The company’s shares closed last Wednesday at $397.58.
Minter has an average return of
According to TipRanks.com, Minter is ranked #1963 out of 8799 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $456.70 average price target, a 14.2% upside from current levels. In a report issued on April 1, Wells Fargo also maintained a Buy rating on the stock with a $540.00 price target.
See today’s best-performing stocks on TipRanks >>
Amylyx Pharmaceuticals Inc (AMLX)
Bank of America Securities analyst Geoff Meacham reiterated a Hold rating on Amylyx Pharmaceuticals Inc yesterday and set a price target of $3.50. The company’s shares closed last Wednesday at $2.46, close to its 52-week low of $2.45.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Amylyx Pharmaceuticals Inc is a Hold with an average price target of $4.36, representing a 67.7% upside. In a report issued on March 27, Goldman Sachs also maintained a Hold rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRTX:
- M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal
- RBC says pain opinion leader ‘notably negative’ on Vertex’s VX-548
- Truist pharmaceuticals analyst holds an analyst/industry conference call
- Vertex announces acceptance of NDS for exagamglogene autotemcel
- Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial
